US29089Q1058 - Common Stock - Premarket: 12.35 +0.58 (+4.93%)
NYSE:EBS (11/29/2022, 7:04:00 PM)+0.16 (+1.38%)
|GICS Sector||Health Care|
|Earnings (Last)||11-08 2022-11-08/amc||Earnings (Next)||01-09 2023-01-09|
|Ins Owners||4%||Inst Owners||81.92%|
Find more stocks on New York Stock Exchange, Inc.
Find more stocks on the USA
Find competitors from the same sector on the USA
Find competitors from the same industry on the USA
Find stocks with similar TA and Setup ratings on the USA
Find stocks with similar Fundamental rating on the USA
Find the competitors with the best technical ratings on the USA
Find the competitors with the best technical and setup ratings on the USA
Find the competitors with the best fundamentals on the USA
Find the competitors with the best valuation on the USA
Find the competitors with the best dividend on the USA
Find the competitors with the best analyst ratings on the USA
Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. The company is headquartered in Gaithersburg, Maryland and currently employs 2,416 full-time employees. The company went IPO on 2006-11-15. The firm is focused on five PHT categories: chemical, biological, radiological, nuclear and explosives (CBRNE); emerging infectious diseases; travel health; public health crises (such as the opioid crisis and the COVID-19 pandemic); acute, emergency, and community care. Its business lines include Medical Countermeasures (MCM), Commercial and CDMO. MCM focuses primarily on procurement of MCM products and procured product candidates by domestic and international government customers. The company provides solutions for PHTs through a portfolio of vaccines and therapeutics that it develops and manufactures for governments and consumers. The company offers TEMBEXA (brincidofovir) an antiviral for the treatment of smallpox in all age groups, including adults, and for patients who have difficulty swallowing.
EMERGENT BIOSOLUTIONS INC
400 Professional Dr, Suite 400
Gaithersburg MARYLAND 20879
CEO: Robert G. Kramer
Emergent partners with the Armed Forces Research Institute of Medical Sciences for its capabilities in Chikungunya virus surveillance and field studies...
Emergent partners with the Armed Forces Research Institute of Medical Sciences for its capabilities in Chikungunya virus surveillance and field studies
Biotech stocks were hammered Wednesday, including several that had good news.
EBS earnings call for the period ending September 30, 2022.
Here you can normally see the latest stock twits on EBS, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.